
PUBLISHED IN **Visionary Vogues** · Magazine column · web
PUBLISHED 23 November 2026
AUTHOR Ravi R. Iyer, MD
SOURCE https://www.visionaryvogues.com/boardroom-reflections-ai-healthcare-purchasing-consortium-ravi-iyer
RECORDED 23 November 2026 · record AR-2026-11-011

THE HEALTHCARE RECKONING · PART 3 OF 4

Can AI Turn America's Employers into the Most Powerful Healthcare Purchasing Consortium in History?

Beyond price transparency: how agentic artificial intelligence, granular pattern recognition, collective purchasing power and direct contracting could change the economics of American healthcare.

By **Ravi R. Iyer, MD**



Key art as published by Visionary Vogues. Retained as part of the record of how the piece appeared.

THE REVOLUTION IS NOT THAT AI CAN FIND A LOWER PRICE

Imagine the following conversation in a corporate boardroom.

The Chief Financial Officer announces that the corporation will spend $150 million on healthcare during the coming year.

- The Chief Executive Officer asks a reasonable question.
- "Are we getting the best possible price?"
- The benefits administrator responds that the company has
- negotiated competitive rates through its insurance carrier and
- pharmacy benefit manager.

> "Competitive with whom?" asks the CEO.
> The administrator cannot say with certainty.

- "How much does the manufacturer actually receive for the
- pharmaceuticals we purchase?"

That information may not be fully available.

> *How much do the intermediaries retain?*

The answer depends on contractual arrangements that may be difficult to audit.

- "Could another employer purchase the same medication for
- less?"
- Possibly.
- "How much less?"
- Nobody knows.
- "Could we negotiate directly?"
- Perhaps.
- "Then why haven't we?"
- Silence.

Now imagine a different conversation.

- The CFO opens an AI-powered healthcare purchasing
- intelligence platform.
- The system has analyzed millions of appropriately licensed and
- accessible pricing records, negotiated-rate disclosures,
- pharmaceutical contracts, claims transactions, utilization
- patterns, and supplier proposals.

It identifies the company's largest pharmaceutical expenditures.

- It compares clinically equivalent products.
- It detects unexplained differences between negotiated prices.
- It estimates the economic consequences of alternative
- purchasing arrangements.

- It identifies other employers with compatible purchasing
- requirements.
- And it produces a negotiation strategy grounded in actual
- purchasing data.
- The CEO asks the same question.
- "Are we getting the best possible price?"

This time, the answer is not an assurance from an intermediary.

> It is an auditable analysis.
> THAT IS THE TRANSFORMATION.

But the real breakthrough is not that artificial intelligence can research competitive prices.

> That capability is hardly novel.
> The breakthrough lies in something far more consequential.

AI can aggregate enormous quantities of disparate, fragmented, inconsistent, and previously difficult-to-compare data, and discover patterns of pricing behavior at a level of granularity that traditional purchasing departments could never practically achieve.

And once those patterns become visible, price opacity becomes increasingly difficult to defend.

I. THE REAL PROBLEM IS NOT A SHORTAGE OF DATA. IT IS A SHORTAGE OF INTELLIGENCE.

- American healthcare generates extraordinary quantities of
- information.
- Hospital negotiated-rate disclosures.
- Insurer transparency files.
- Medicare reimbursement schedules.
- Pharmaceutical pricing benchmarks.
- Prescription claims.
- Employer benefit contracts.
- Provider networks.
- Laboratory billing schedules.
- Clinical outcomes.
- Drug formularies.
- Administrative fee schedules.
- Patient cost-sharing arrangements.
- And millions of individual transactions.

The information is fragmented across institutions, contractual relationships, coding systems, data formats, and commercial arrangements.

- Some is publicly available.
- Some is proprietary.
- Some is accessible only through contractual audit rights.

- Some is protected health information.

And some of the most economically consequential information, such as confidential net pharmaceutical rebates, may not be available to an outside analyst at all.

- But the existence of incomplete data does not mean the
- available data are useless.

It means the intelligence required to integrate them has historically been expensive, labor-intensive, and difficult to scale.

A conventional purchasing analyst may compare dozens of contracts. A sophisticated consulting team may compare hundreds. An appropriately engineered AI system can potentially process millions of records, identify inconsistencies, normalize terminology, reconcile coding systems, and uncover patterns across enormous datasets.

This changes the economics of information.

- The question is no longer simply:
- Can we obtain a price?
- It becomes:
- Can we reconstruct the economic behavior of an entire
- healthcare marketplace from the patterns embedded in its
- transactions?

> That is a very different proposition.
> And it is where the true opportunity begins.

II. FROM PRICE DISCOVERY TO PRICE INTELLIGENCE

Consider a common diagnostic procedure.

An employer discovers that one imaging center charges $800 for an MRI while another charges $2,400.

> That is useful information.
> But it is not yet purchasing intelligence.

- Are both prices for the same examination?
- Do they include contrast?
- Are professional interpretation fees included?
- Is one performed in a hospital outpatient department?
- Does the other involve a freestanding imaging center?
- Are the patients clinically comparable?
- Are the charges actually paid amounts or merely published
- prices?
- Does either facility have better diagnostic quality, access, or
- turnaround time?

The superficial comparison may be misleading.

- Now imagine an AI system capable of normalizing those

- differences.
- It identifies the precise procedure code.
- It distinguishes technical from professional components.
- It accounts for the site of service.
- It compares actual negotiated amounts where available.
- It identifies contractual exclusions.
- It incorporates geographic market conditions.
- It examines quality indicators.
- And it generates a comparison of the total cost of clinically
- equivalent services.
- The output is no longer simply a list of prices.
- It is an economic map of the transaction.

PRICE TRANSPARENCY TELLS YOU WHAT SOMEONE CHARGES.

PRICE INTELLIGENCE HELPS YOU UNDERSTAND WHY THEY CHARGE IT, WHETHER THE COMPARISON IS VALID, AND WHAT YOU COULD REASONABLY NEGOTIATE INSTEAD.

That distinction is fundamental.

And it becomes exponentially more powerful when applied across thousands of services and millions of transactions.

III. THE GRANULARITY REVOLUTION: WHEN OPACITY BECOMES A DETECTABLE PATTERN

Here is where artificial intelligence changes the equation.

Imagine an employer purchasing pharmaceutical benefits for 25,000 employees.

A conventional analysis might identify the 20 most expensive medications.

An AI-enabled system could go much further.

It could examine each medication across multiple dimensions:

National Drug Code, formulation, strength, dosage and package size. Brand versus generic or biosimilar alternatives. Pharmacy acquisition benchmarks and reimbursement arrangements. Manufacturer rebates and fees where contractually available. Dispensing channels, including retail, mail order and specialty pharmacy. Geographic pricing differences. Patient cost-sharing and formulary placement. Net employer expenditure after all known credits and administrative costs. Clinical equivalence, prescribing appropriateness and therapeutic outcomes.

The system could then identify anomalous patterns.

Why does one employer pay materially more than another for a comparable medication? Why does a specialty pharmacy channel generate higher total expenditure than an alternative distribution arrangement? Why does a product with a lower acquisition price produce a higher net employer cost? Why does a drug with a substantial manufacturer rebate remain more expensive than a clinically appropriate alternative? Why do apparently similar contracts produce dramatically different financial outcomes?

> Some differences will have legitimate explanations.
> Others may reveal inefficiency.

Still others may expose compensation structures that deserve independent examination.

- AI can rank these anomalies by their potential economic
- significance.

It can distinguish patterns supported by strong evidence from those based on incomplete data. It can generate specific questions for contract audits. And it can continuously monitor whether negotiated savings actually materialize.

The extraordinary capability is not merely finding the lowest price. It is identifying the fingerprints of pricing opacity across an entire marketplace.

IV. THE POWER OF PATTERN MATCHING: RECONSTRUCTING THE INVISIBLE MARKET

There is an important conceptual shift here.

Traditional price comparison begins with known products and asks how much they cost.

- AI-enabled pattern analysis can begin with millions of
- transactions and ask what hidden economic relationships might
- explain their differences.

- Consider a hypothetical dataset involving 100 employers,
- thousands of pharmacies, and millions of prescription
- transactions.

- The system identifies clusters of apparently comparable
- purchases.

- It discovers that certain employers consistently experience
- higher net expenditure for particular drug categories.

It identifies relationships between formulary placement, rebate structures, specialty distribution, and employer cost.

It detects that a contract advertised as providing substantial discounts may nevertheless produce higher total expenditure than a contract with smaller nominal discounts.

It identifies pricing outliers that cannot readily be explained by geography, product differences, or dispensing costs.

> These observations become hypotheses.
> The AI system then seeks corroborating evidence.

- It examines available contract provisions.
- It compares reimbursement formulas.
- It checks public price benchmarks.
- It requests authorized documentation.
- It identifies gaps requiring human review.

The result is a progressively more detailed understanding of market behavior.

This is not the same as discovering a confidential price that has never been disclosed.

AI cannot magically know a secret rebate or reconstruct an exact net price when the necessary evidence does not exist.

But it can identify patterns consistent with hidden economic differences, estimate plausible ranges where assumptions are justified, and determine precisely what additional information would be needed to verify them.

That is enormously valuable.

Because the greatest commercial advantage of opacity is often not that the underlying information is impossible to discover.

- It is that discovering it has historically been too expensive,
- complicated, or time-consuming to justify.

AI changes that calculation.

V. FROM INDIVIDUAL PURCHASERS TO COLLECTIVE INTELLIGENCE

Now consider the next step.

A corporation with 5,000 employees has meaningful purchasing power.

A corporation with 50,000 employees has considerably more.

But what happens when 100 corporations with 5,000 employees each discover that they are purchasing many of the same pharmaceuticals, diagnostic services, and healthcare benefits?

Collectively, they represent 500,000 employees.

- Their purchasing requirements overlap.
- Their negotiating objectives overlap.
- Their need for transparency overlaps.

Yet each may be negotiating through a separate insurer, PBM, consultant, or administrative arrangement.

The fragmentation of purchasing power benefits those who negotiate against fragmented purchasers.

WHAT IF ARTIFICIAL INTELLIGENCE COULD REVERSE THAT FRAGMENTATION?

- Imagine an AI-enabled platform that helps independent
- employers identify opportunities for collective purchasing.

It analyzes their aggregate pharmaceutical demand.

It identifies common drug categories. It estimates purchasing volumes. It evaluates geographic concentration. It identifies clinically appropriate opportunities for standardized contracting. It prepares requests for proposals. It compares manufacturer offers. It models the economic consequences of different contract structures. And it monitors whether suppliers honor the negotiated terms.

- The employers retain their independence.
- Their employees retain access to individualized medical care.
- Physicians retain clinical authority.
- But the purchasing function becomes coordinated.
- The result could be a fundamentally different negotiating
- relationship.

Instead of one employer negotiating against a sophisticated national supplier, a legally structured purchasing consortium could negotiate on behalf of a much larger population.

THE REVOLUTION IS NOT THAT AI REPLACES THE PURCHASER.

- IT IS THAT AI MAKES COLLECTIVE PURCHASING INTELLIGENCE
- AVAILABLE TO EMPLOYERS THAT COULD NEVER BUILD IT
- INDIVIDUALLY.

VI. THE AI-ENABLED EMPLOYER HEALTHCARE PURCHASING CONSORTIUM

> Let us give this concept a working name.
> THE EMPLOYER HEALTHCARE INTELLIGENCE CONSORTIUM.

- Not another insurance company.
- Not another opaque pharmacy benefit manager.
- Not another intermediary whose profits depend on undisclosed
- spreads.

But a purchasing infrastructure designed to serve the employers who finance healthcare.

Its architecture would contain six essential capabilities.

1. Data aggregation and normalization

- The consortium would ingest authorized claims, contracts,
- public price disclosures, supplier proposals, pharmaceutical
- benchmarks, and clinical quality data.
- AI would standardize coding, reconcile terminology, identify
- missing information, and distinguish comparable from
- noncomparable transactions.
- The objective would be a common economic language for
- healthcare purchasing.

1. Granular price intelligence

The platform would calculate verified net costs wherever the necessary data are available.

It would identify unexplained pricing variation, administrative compensation, contract anomalies, and potential opportunities for direct negotiation.

Where data are incomplete, it would report uncertainty rather than manufacture precision.

1. Collective demand forecasting

- Participating employers would contribute aggregated
- purchasing requirements through privacy-preserving
- arrangements.
- The system would identify overlapping demand, forecast
- utilization, and determine where pooled purchasing could
- create meaningful leverage.

1 Agentic negotiation support

AI agents could research supplier options, prepare requests for proposals, compare contractual terms, model counteroffers, and flag unfavorable provisions.

- Authorized human representatives would approve binding
- commitments.

The system would not autonomously make medical decisions or enter major financial obligations without appropriate oversight.

1 Independent clinical evaluation

A physician- and pharmacist-led committee would evaluate clinical equivalence, therapeutic effectiveness, safety, access, and quality.

Lower price alone would never be sufficient justification for a clinically inferior intervention.

1 Continuous contract auditing

AI would compare actual claims and invoices with negotiated contract terms.

- It would identify discrepancies, verify credits, monitor service
- quality, and report whether projected savings were actually
- realized.
- The goal would be to transform purchasing from an annual
- negotiation into a continuous, accountable process.

VII. THE NEW ECONOMICS OF COLLECTIVE PURCHASING

Consider an illustrative consortium of 100 employers, each with 5,000 employees.

That represents 500,000 employees.

- Assume, purely for illustration, annual pharmacy benefit
- spending of $2,000 per employee.
- The consortium would represent approximately $1 billion in
- annual pharmaceutical expenditure.

THE PURCHASING POWER OF SCALE

Illustrative scenario — not a forecast of achievable savings

- Participating employers
- 100
- Employees per employer

- 5,000
- Annual drug spending per employee
- $2,000
- Assumed net savings
- 10%
- Collective covered employees
- 500,000
- Annual purchasing volume
- $1.00B
- Potential annual savings
- $100.0 million

Assumes each employee represents one spending unit. Excludes dependents, consortium costs, changes in utilization and implementation expenses. Actual savings could be smaller, zero, or negative.

At an illustrative 10% net savings rate, that would represent $100 million annually.

But the real significance is not the hypothetical number.

- It is the possibility of creating a purchasing organization with the
- negotiating sophistication and market visibility of a major
- national enterprise— without requiring every participating
- employer to build its own infrastructure.

> The economics of purchasing intelligence would be shared.
> The benefits of purchasing leverage could be shared.

- And the administrative costs of developing the intelligence
- could be distributed across the consortium.
- That is the promise of scale.

VIII. DIRECT CONTRACTING: DO WE REALLY NEED EVERY MIDDLEMAN?

Now consider pharmaceutical purchasing.

- Why must every employer negotiate through the same
- conventional intermediary structure?
- Could a consortium negotiate directly with pharmaceutical
- manufacturers?

In some circumstances, yes.

Could it establish transparent cost-plus pharmacy distribution arrangements?

- Yes, subject to licensing, contracting, and operational
- requirements.

Could it use an independent claims administrator compensated through a fixed fee?

Yes.

Could it retain pharmacists and physicians to oversee clinical appropriateness without tying their compensation to drug-price spreads?

Yes.

Could it negotiate separate arrangements for high-cost specialty medications?

> Potentially.
> Could it evaluate outcomes-based pharmaceutical contracts?

Yes, where the outcomes are measurable, the data reliable, and the financial terms workable.

The critical distinction is between the economic functions and the organizations currently performing them.

- Claims must still be processed.
- Medications must still be dispensed.
- Patients must still receive appropriate counseling.
- Drug safety must still be monitored.
- Formularies must still be clinically governed.
- Specialty medications may require sophisticated distribution
- and support.
- But none of these functions inherently requires opaque
- compensation.

THE OBJECTIVE IS NOT TO ELIMINATE EVERY INTERMEDIARY.

- IT IS TO ELIMINATE THE ECONOMIC REWARD FOR
- UNNECESSARY INTERMEDIATION.

- Pay for administration.
- Pay for distribution.
- Pay for clinical expertise.
- Pay for measurable service.

But do not confuse the cost of providing a service with the opportunity to profit from controlling information about its price.

IX. FROM DRUGS TO THE ENTIRE HEALTHCARE MARKETPLACE

The opportunity extends far beyond pharmaceuticals.

Imagine applying the same purchasing intelligence to laboratory services.

AI identifies clinically equivalent tests performed by different laboratories.

It compares bundled prices, turnaround times, quality measures, and contractual terms.

> The consortium negotiates transparent rates.
> Now consider imaging.

- MRI.

- CT.
- Ultrasound.
- Cardiac imaging.
- The system compares total episode prices, facility fees,
- interpretation charges, and appropriate quality indicators.

It identifies opportunities to shift elective, clinically equivalent services toward more efficient providers without compromising care.

Now consider planned surgical procedures.

The platform compares bundled episode prices, complication rates, readmissions, patient outcomes, and total expenditure.

- It helps employers negotiate with high-quality centers of
- excellence.

Now consider chronic disease management.

- Diabetes.
- Hypertension.
- Obesity.
- Cardiovascular disease.
- Chronic kidney disease.
- The consortium evaluates programs not simply by the number
- of visits, tests, or prescriptions delivered, but by evidence-
- supported outcomes and total economic value.

And now the purchasing question begins to change.

Instead of asking: How cheaply can we purchase another episode of medical care?

- The employer begins asking:
- What investments can reduce the probability that the episode
- becomes necessary in the first place?

That is the bridge between purchasing intelligence and health intelligence.

And it is the foundation for the final installment of this series.

X. THE DANGER: AI COULD ALSO MAKE THE EXISTING SYSTEM WORSE

There is an important warning.

Artificial intelligence is not inherently a force for transparency.

The same technology that allows employers to identify price opacity could allow suppliers to optimize prices, segment purchasers, and extract the maximum amount each customer is willing to pay.

The same algorithms that identify unnecessary expenditure could be used to deny necessary care.

- The same data analytics that identify health risks could be
- misused to discriminate against employees with costly medical
- conditions.

The same consortium that creates purchasing leverage could become an instrument of excessive market concentration or unlawful coordination.

And competing suppliers must not use shared AI systems to coordinate prices or other competitively sensitive conduct.

> Technology does not determine whose interests are served.
> Governance does.

An employer purchasing consortium must therefore be built around enforceable principles.

Patient medical information must remain protected.

Employers should receive aggregated purchasing intelligence, not individual employee diagnoses or predictive risk profiles.

> Clinical decisions must remain independent.
> Pricing comparisons must be auditable.
> AI-generated estimates must disclose uncertainty.

Contracts must comply with antitrust and other applicable laws.

And financial rewards must be tied to genuine economic and clinical value.

AN AI SYSTEM THAT MAKES OPAQUE PRICING MORE EFFICIENT IS NOT A REVOLUTION.

IT IS MERELY A MORE SOPHISTICATED FORM OF THE SAME PROBLEM.

The revolution occurs only when intelligence is aligned with the interests of the purchaser and the patient.

XI. THE TRUE MEASURE OF VALUE: WHAT HAPPENS TO THE HUMAN BEING?

Let us return to the fundamental question.

- What is healthcare supposed to accomplish?
- Is the objective to reduce claims?
- Lower premiums?
- Increase insurer margins?
- Generate shared savings?
- Improve the performance of a purchasing consortium?

> These may be legitimate financial objectives.
> But none is the ultimate purpose of medicine.

- The ultimate purpose is the preservation and restoration of
- human function, the reduction of suffering, and the expansion of

- the possibilities available during a human life.

A lower pharmaceutical price is valuable when the medication remains clinically appropriate and accessible.

A lower imaging price is valuable when diagnostic quality is maintained. A lower hospital expenditure is valuable when unnecessary complications are prevented— not when necessary care is withheld. A lower total healthcare cost is valuable when it reflects genuine efficiency rather than the transfer of financial burdens to patients.

THE GOAL IS NOT TO PURCHASE THE LEAST HEALTHCARE.

- THE GOAL IS TO PURCHASE THE GREATEST ACHIEVABLE
- HEALTH VALUE.
- And this is where the limitations of traditional value-based
- purchasing become apparent.
- If the reward structure depends on continually lowering
- expenditure benchmarks, providers may eventually be penalized
- for the durability of their own success.

If the financing structure rewards intermediaries for managing transactions rather than improving outcomes, complexity can become profitable.

If the purchaser lacks transparency, even the most sophisticated contracting arrangement may fail to produce accountability.

- A genuine value-based system must be capable of
- distinguishing financial savings from biological value.
- And it must reward both appropriately.

XII. FROM BLINDNESS TO VISIONARY: THE BOARDROOM'S NEW RESPONSIBILITY

The modern corporation understands enterprise management.

- It forecasts revenue.
- It monitors costs.
- It measures performance.
- It evaluates risk.
- It negotiates contracts.
- It invests in future productivity.
- It manages supply chains.
- It audits financial transactions.
- It holds executives accountable for results.
- Yet when it comes to healthcare, the corporation has often
- accepted a remarkably passive role.
- It purchases insurance.
- It delegates administration.

- It receives annual renewal proposals.
- It negotiates premium increases.
- And it absorbs the financial consequences.

What if the boardroom demanded the same discipline from healthcare purchasing that it demands from every other major enterprise function?

What if the CFO could see the true economics of pharmaceutical purchasing? What if the CHRO could evaluate healthcare benefits based on employee access, experience, and outcomes? What if the Chief Risk Officer could distinguish preventable clinical risk from unavoidable medical uncertainty? What if the CEO could compare healthcare purchasing strategies with the same rigor applied to capital investment?

And what if these executives could combine their purchasing intelligence with that of hundreds of other employers?

The result would not merely be a stronger negotiating position.

It could be a new form of healthcare market governance.

- PURCHASING POWER WITHOUT INTELLIGENCE IS BLUNT
- FORCE.
- INTELLIGENCE WITHOUT PURCHASING POWER IS AN
- ACADEMIC EXERCISE.
- BUT INTELLIGENCE COMBINED WITH COLLECTIVE
- PURCHASING POWER CAN BECOME A FORCE FOR
- STRUCTURAL CHANGE.

That is the proposition.

- Not that AI will magically solve healthcare.
- Not that employers should practice medicine.
- Not that every intermediary is unnecessary.

But that the people financing healthcare should no longer be required to purchase it blindly.

XIII. THE NEXT QUESTION: WHY STOP AT PURCHASING?

Suppose the employer consortium succeeds.

- Pharmaceutical prices become more transparent.
- Administrative compensation becomes auditable.
- Laboratory and imaging contracts become more competitive.
- Providers are rewarded for genuine clinical value.
- Healthcare expenditures become more intelligible.

> What comes next?
> The answer is both obvious and revolutionary.

- WHY CONTINUE ORGANIZING HEALTHCARE PRIMARILY
- AROUND THE FINANCING OF DISEASE?

Why not organize it around the intelligent management of health? Why not distinguish catastrophic financial protection from the routine financing of healthcare? Why not create more flexible personal health accounts? Why not invest in clinically justified prevention before catastrophic expenditure occurs? Why not use AI to help physicians integrate longitudinal biomarkers, clinical history, risk factors, and scientific evidence? Why not measure healthcare value across the trajectory of a human life rather than merely across an annual insurance contract? And why not reward physicians for maintaining durable improvements in health instead of repeatedly resetting financial benchmarks against their previous success?

This is where the purchasing revolution becomes something larger.

It becomes a new social contract.

A contract in which insurance protects against catastrophe.

> Purchasing intelligence makes the market more accountable.
> Physicians retain clinical independence.
> Patients retain agency.

- And the financing of healthcare begins to recognize the
- difference between paying for medical events and investing in
- human health.

The transition from blindness to vision is not complete when we can finally see the price.

IT IS COMPLETE ONLY WHEN WE CAN CONNECT THE PRICE TO THE VALUE OF THE LIFE IT IS INTENDED TO SERVE.

NEXT IN THE SERIES | PART 4 BEYOND INSURANCE: THE ENTERPRISE OF HUMAN HEALTH

- The New Social Contract for a Healthier, More Productive
- America
- November 30, 2026 | 4:00 PM Eastern
- In the final installment, we move beyond the economics of
- purchasing to the architecture of healthcare itself.

Can catastrophic financial protection be separated from the routine financing of healthcare? Can expanded personal health accounts create more direct purchasing power? Can employer purchasing consortiums make healthcare markets more competitive? Can AI-enabled clinical intelligence help physicians manage health trajectories rather than simply respond to medical catastrophes?

- And can we construct a financing system in which preserving
- human health becomes economically more valuable than
- repeatedly treating preventable dysfunction?

The future of healthcare cannot be defined merely by who pays for disease.

It must be defined by how intelligently we invest in life.

ABOUT THE AUTHOR

Ravi R. Iyer, MD, is a physician-scientist, entrepreneur, author, and 5x TEDx speaker who has spent four decades exploring a deceptively simple question: What makes human beings— and the organizations they create— perform at their best? A Harvard-trained physician, corporate strategist, and the founder of multiple healthcare and performance ventures, he is the creator of Neuroalignment, a framework for building high-performance organizations around the realities of human cognitive diversity. His work sits at the intersection of biology, leadership, technology, and human behavior. Boardroom Reflections is where those worlds meet.

THE AKAASHIK RECORD

A permanent, complete and unedited register of the writing and public work of Ravi R. Iyer, MD. Each entry records where the work first appeared, when, and at what address, so that the record stands independently of any platform that carries it. Entries are never removed. © Ravi R. Iyer, MD. Recorded by arrangement with the original publisher; all rights in the original publication remain with its owner.

Name forms. One person, credited as Ravi R. Iyer, MD; Ravi R. Iyer; Ravi Ramamoorthy Iyer, MD; Ravi Ramamoorthy Iyer; Ravi Iyer, MD; Ravi Iyer; Ravi Ramamoorthy; R. R. Iyer; R.R. Iyer; R. Iyer. The author's name is Ravi Iyer, and has been for many years. His work is nonetheless credited under several forms. In India the canonical surname is Ramamoorthy and Iyer is the clan name appended to it, and where a form is entered under that convention the credit follows it: on the signed speaker release for TEDxChantilly he entered Ravi Ramamoorthy Iyer, and that talk stands credited on the TEDx channel to Ravi Ramamoorthy. The five ted.com event pages credit him under four different forms between them — Dr. Ravi Iyer at TEDxGary, Dr. Ravi Iyer, MD at TEDxHandley Blvd Women, R.R. Iyer at TEDxUMKC, and Ravi Ramamoorthy Iyer at both TEDxMontgomery College and TEDxChantilly HS. The Record lists every form the work is credited under, so that it remains findable under each.